亚虹医药：APL-1702 上市许可申请获欧洲药品管理局受理

Core Viewpoint - The company, Yahuang Pharmaceutical, has received notification from the European Medicines Agency (EMA) regarding the acceptance of its marketing authorization application for product APL-1702 (CEVIRA) intended for the treatment of high-grade squamous intraepithelial lesions (HSIL) in patients [1] Group 1 - The marketing authorization application for APL-1702 has been accepted by the EMA, indicating a step forward in the regulatory process [1] - Following the acceptance, the product must still undergo further review and approval stages, introducing uncertainty regarding its successful market launch and specific timing [1] - Even if approved, there remains uncertainty about the product's ability to achieve commercial objectives [1] Group 2 - The acceptance of the marketing authorization application is not expected to have a significant impact on the company's recent performance [1]